Bone marrow transplantation for myeloblastoma

Abstract

A 20‐yr‐old man with bulky mediastinal and retroperitoneal tumour masses identified as myeloblastoma is described. After a partial remission was induced by aggressive chemotherapy, mediastinal irradiation and retroperitoneal tumour resection, the patient received an allogeneic marrow graft from his HLA‐identical sister. The conditioning regimen consisted of high‐dose busulfan and cyclophosphamide. The patient has a well‐controlled secondary chronic graft‐versus‐host disease. He is in unmaintained complete remission and in good general condition at 20 months post‐transplantation.

Isolated granulocytic sarcoma of the small intestine successfully treated with chemotherapy and bone marrow transplantation

“…2 Histology of the surgical specimen demonstrated diffuse infiltration of medium to large cells with conspicuous nucleoli. a HE staining, b immunohistochemical staining of CD34, and c myeloperoxidase staining publication [6,[13][14][15][16][17][18][19]. Their mean disease-free survival period was reported to be 27.3 months (12-48 months) after stem cell transplantation.…”

Successful Treatment of Duodenal Myeloid Sarcoma with Allogeneic Bone Marrow Transplantation and Additional Radiotherapy

“…Previous reports have described patients with chemoresistant MS or MS with an unfavorable prognosis who were treated with allo-HCT (5-11). In some cases involving a large mass or multiple lesions, long-term survival was achieved by performing the transplant with the patient in a non-CR state; however, these lesions make accurate evaluation of the extent of any residual disease remaining after chemotherapy difficult (7)(8)(9). On the other hand, some case reports demonstrated that MS relapsed after allo-HCT for leukemia (12,13).…”

Refractory de novo myeloid sarcoma: a case report and therapeutic strategy based on bone marrow minimal residual disease

“…Although Yamauchi et al [6] reported that 26% of de novo MS patients who had received intensive chemotherapy developed AML with extremely poor prognosis, in recent years, some case reports suggesting the efficacy of allogeneic hematopoietic stem cell transplantation (HSCT) which may bring about the long-term CR of de novo MS have been published [7][8][9][10][11][12]. In the present patient, we did not observe residual and recurrent leukemia despite highly refractory AML before HSCT, although the period of follow-up was short.…”